Idarubicin: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Idarubicin, so there is currently no new predicted indication. The drug’s recorded uses are listed below; they are the drug’s own known uses, not model candidates.
Quick overview
Item
Content
New predicted indications
None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug
15
Evidence level
Not applicable
Australia Market Status
Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items
1 (valid: 1)
Known uses recorded for this drug
Approved (supported by a licence or label)
Indication
Source
none
none
Related to an approved indication (same disease category)
Indication
Approved category
none
none
Relations recorded in the knowledge graph (no approval found)
Indication
acute myeloblastic leukemia with maturation
acute myeloblastic leukemia without maturation
acute myeloid leukemia with cebpa somatic mutations
acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2)
acute myeloid leukemia with minimal differentiation
acute myeloid leukemia with npm1 somatic mutations
acute myeloid leukemia with t(6;9)(p23;q34)
acute myeloid leukemia with t(8;16)(p11;p13) translocation
acute myeloid leukemia with t(8;21)(q22;q22) translocation
acute myeloid leukemia with t(9;11)(p22;q23)
acute promyelocytic leukemia
inherited acute myeloid leukemia
myeloid leukemia
therapy related acute myeloid leukemia and myelodysplastic syndrome
unclassified acute myeloid leukemia
Australia Market Information
Licence
Product
Dosage form
Status
4440Q
Zavedos Solution
Solution for I.V. injection containing i
Valid
Cytotoxicity
Item
Content
Cytotoxicity Classification
Conventional cytotoxic (anthracycline class)
Myelosuppression Risk
High (severe myelosuppression is a recognised effect of anthracyclines; please confirm in the Product Information)
Emetogenicity Classification
Moderate (class-based; please confirm in the Product Information)
Monitoring Items
FBC with differential, liver and renal function, cardiac function (e.g. echocardiography or MUGA)
Handling Protection
Must follow cytotoxic drug handling regulations
Please refer to the Product Information (PI) warnings and precautions for product-specific details.
Safety Considerations
Disease associations flagged in the knowledge graph (not label text): kidney disease, liver disease, gallbladder disease, anaemia, sudden cardiac arrest, heart conduction disease, cardiomyopathy (including hypertrophic), endomyocardial fibrosis, myocardial disorders, pericarditis, myocarditis, enterocolitis and gastroenteritis. These come from a model knowledge graph and must be verified against the PI.
Drug interactions: The interaction search returned 100 records; 20 were available for review. Major interactions include:
Dolasetron
Cisapride
Papaverine
Deferiprone
Macimorelin
Moderate interactions include ondansetron, granisetron, palonosetron, clarithromycin, levofloxacin, famotidine, loperamide, promethazine, rolapitant, eliglustat and palifermin. Several of these are QT-prolonging or antiemetic agents, which is relevant to a drug with cardiac toxicity. Bowel-preparation products (picosulfuric acid, polyethylene glycol with electrolytes, sodium sulfate) are also listed as moderate interactions. Metronidazole is a minor interaction.
Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.